Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency

详细信息    查看全文

• 作者：Doyun Park MD ; William Southern MD ; MS…
• 关键词：dalteparin ; renal insufficiency ; bleed ; heparin
• 刊名：Journal of General Internal Medicine
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：31
• 期：2
• 页码：182-187
• 全文大小：335 KB
• 参考文献：1. Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA. 2014;311:717–728.CrossRef PubMed
  2. Alqiwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A review of the pharmacology, dosing, and complications. Curr Emerg Hosp Med Rep. 2013;21(1):83–97.CrossRef
  3. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688–698.CrossRef PubMed
  4. Gouin-Thibault I, Pautas E, Sigueret V. Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf. 2005;28:333–349.CrossRef PubMed
  5. Lee AY, Levine MN, Baker RI, et al. Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153.CrossRef PubMed
  6. Green B, Greenwood M, Saltissi D, et al. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol. 2005;59:281–290.PubMedCentral CrossRef PubMed
  7. Siguret V, Pautas E, Février M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84:800–804.PubMed
  8. Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf. 2002;25:725–733.CrossRef PubMed
  9. Spyropoulos AC, Mahan C. Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am J Med. 2009;122:1077–1084.CrossRef PubMed
  10. Shprecher AR, Cheng-Lai A, Madsen EM, et al. Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy. 2005;25:817–822.CrossRef PubMed
  11. Holbrook A, Schulman S, Witt DM, et al. On behalf of the American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S–e184S.PubMedCentral CrossRef PubMed
  12.Fragmin (dalteparin) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; August 2014.
  13. Schulman S. Kearon C on behalf of the subcommittee on control of anticoagulation of the Scientific and Standardization committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Scientific and Standardization Committee Communication. J Thromb Haemost. 2005;3:692–694.CrossRef PubMed
  14. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143:753–759.CrossRef PubMed
  15. DeCarolis DD, Thorson JG, Clairmont MA, Leuthner AM, Rector TS, Johnson GJ. Enoxaparin outcomes in patients with moderate renal impairment. Arch Intern Med. 2012;172:1713–1718.CrossRef PubMed
  16. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol. 2003;43:586–590.CrossRef PubMed
  17. Trujillo-Santos J, Schellong S, Falga C, et al. Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. Am J Med. 2013;126:425–434.CrossRef PubMed
  18. Johansen KB, Balchen T. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance? Exp Hematol Oncol. 2013;2:21.PubMedCentral CrossRef PubMed
  19. Peyrou V, Lormeau JC, Caranobe C, et al. Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit. Thromb Haemost. 1994;72:268–274.PubMed
  20. Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost. 1987;58:932–935.PubMed
  21. Johansen KB, Schroeder M, Lundtorp L, Mousa SA. Renal elimination of tinzaparin versus enoxaparin in normal versus nephrectomized rats. J Thromb Haemost. 2007;5(Suppl 2):629.
  22. Collignono F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparin—dalteparin, enoxaparin and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995;73:630–640.
  23. Rabbat CG, Cook DJ, Crowther MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care. 2005;20:357–363.CrossRef PubMed
  24. Saheb Sharif-Askari F, Syed Sulaiman SA, Saheb Sharif-Askari N, Al Sayed Hussain A, Railey MJ. Adverse outcomes of anticoagulant use among hospitalized patients with chronic kidney disease: a comparison of the rates of major bleeding events between unfractionated heparin and enoxaparin. PLoS One. 2014;9:e106517.PubMedCentral CrossRef PubMed
  25. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest. 2004;125:856–863.CrossRef PubMed
  26. Levine MN, Planes A, Hirsh J, et al. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost. 1989;62:940–944.PubMed
  27. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res. 2002;105:225–231.CrossRef PubMed
  28. Tincani E, Mannucci C, Casolari B, et al. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica. 2006;91:976–979.PubMed
  29. Schmid P, Brodmann D, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost. 2009;7:552–558.CrossRef PubMed
  30. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144:673–684.CrossRef PubMed
  31. Oldgren J, Johnston N, Siegbahn A. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. Am Heart J. 2008;155:493.e1-8.CrossRef PubMed
  32. Dufour B, Toussaint-Hacquard M, Kearney-Schwartz A, et al. Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin. J Nutr Health Aging. 2012;16:647–652.CrossRef PubMed
  
• 作者单位：Doyun Park MD (1)
  William Southern MD, MS (2)
  Manuela Calvo MD (2)
  Margarita Kushnir MD (3)
  Clemencia Solorzano RPH (4)
  Mark Sinnet PharmD (4)
  Henny H. Billett MD, MSc (3)
  
  1. Division of Hematology-Oncology, Mount Sinai-Roosevelt Hospital, 1000 Tenth Avenue, New York, NY, USA
  2. Division of Hospital Medicine, Department of Medicine, Montefiore Medical Center of Albert Einstein College of Medicine, Bronx, NY, USA
  3. Division of Hematology, Department of Oncology, Montefiore Medical Center of the Albert Einstein College of Medicine, Bronx, NY, USA
  4. Department of Pharmacy, Montefiore Medical Center, Bronx, NY, USA
  
• 刊物主题：Internal Medicine;
• 出版者：Springer US
• ISSN：1525-1497

文摘